EUVIMEDEUVIMED entdecken
Open Access

IL-13Rα2/TGF- β bispecific CAR-T cells counter TGF- β -mediated immune suppression and potentiate anti-tumor responses in glioblastoma

Andrew J Hou, Ryan M Shih iD, Benjamin R Uy, Amanda Shafer, ZeNan L Chang, Begonya Comin-Anduix, Miriam Guemes, Zoran Galic, Su Phyu, Hideho Okada iD, Katie B Grausam, Joshua J Breunig und 4 weitere

Neuro-Oncology · 03.10.2024 · 26 (10) · 1850-1866

DOI: 10.1093/neuonc/noae126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 03.10.2024. Verfasst von Andrew J Hou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Glioblastoma, Interleukin-13 Receptor alpha2 Subunit, Receptors, Chimeric Antigen, Transforming Growth Factor beta. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR)-T cell therapies targeting glioblastoma (GBM)-associated antigens such as interleukin-13 receptor subunit alpha-2 (IL-13Rα2) have achieved limited clinical efficacy to date, in part due to an immunosuppressive tumor microenvironment (TME) characterized by inhibitory molecules such as transforming growth factor-beta (TGF-β). The aim of this study was to engineer more potent GBM-targeting CAR-T cells by countering TGF-β-mediated immune suppression in the TME.

Methods

We engineered a single-chain, bispecific CAR targeting IL-13Rα2 and TGF-β, which programs tumor-specific T cells to convert TGF-β from an immunosuppressant to an immunostimulant. Bispecific IL-13Rα2/TGF-β CAR-T cells were evaluated for efficacy and safety against both patient-derived GBM xenografts and syngeneic models of murine glioma.

Results

Treatment with IL-13Rα2/TGF-β CAR-T cells leads to greater T-cell infiltration and reduced suppressive myeloid cell presence in the tumor-bearing brain compared to treatment with conventional IL-13Rα2 CAR-T cells, resulting in improved survival in both patient-derived GBM xenografts and syngeneic models of murine glioma.

Conclusions

Our findings demonstrate that by reprogramming tumor-specific T-cell responses to TGF-β, bispecific IL-13Rα2/TGF-β CAR-T cells resist and remodel the immunosuppressive TME to drive potent anti-tumor responses in GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaInterleukin-13 Receptor alpha2 SubunitReceptors, Chimeric AntigenTransforming Growth Factor betaImmunotherapy, AdoptiveXenograft Model Antitumor AssaysTumor MicroenvironmentBrain NeoplasmsAnimalsHumansMiceT-LymphocytesTumor Cells, CulturedCell Line, Tumor

Stichwörter der Autor:innen

CAR-T cell therapyTGF-βglioblastomaimmunotherapytumor microenvironment

Substanzen

Interleukin-13 Receptor alpha2 SubunitReceptors, Chimeric AntigenTransforming Growth Factor betaIL13RA2 protein, human

Autor:innen und Institutionen

  • Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, California, USA.
  • Department of Molecular Biology, University of California, Los Angeles, California, USA.
  • Department of Neurosurgery, University of California, Los Angeles, California, USA.
  • Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California, USA.
  • Department of Surgery, University of California, Los Angeles, California, USA.
  • Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA.

ORCID-Profile: Ryan M Shih, Hideho Okada, Robert M Prins, Yvonne Y Chen

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS
  • NIGMS NIH HHS
  • Mark Foundation for Cancer Research
  • The National Cancer Institute
  • National Institute of Neurological Disorders and Stroke
  • Jean and Stephen Kaplan
  • UCLA Jonsson Comprehensive Cancer Center

Zitieren

APA

Hou, A. J., Shih, R. M., Uy, B. R., Shafer, A., Chang, Z. L., Comin-Anduix, B., Guemes, M., Galic, Z., Phyu, S., Okada, H., Grausam, K. B., Breunig, J. J., Brown, C. E., Nathanson, D. A., Prins, R. M., & Chen, Y. Y. (2024). IL-13Rα2/TGF- β bispecific CAR-T cells counter TGF- β -mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro-Oncology, 26(10), 1850-1866. https://doi.org/10.1093/neuonc/noae126

Vancouver

Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZL, Comin-Anduix B, et al. IL-13Rα2/TGF- β bispecific CAR-T cells counter TGF- β -mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro-Oncology. 2024;26(10):1850-1866. doi:10.1093/neuonc/noae126

BibTeX
@article{Hou2024,
  author = {Hou, Andrew J and Shih, Ryan M and Uy, Benjamin R and Shafer, Amanda and Chang, ZeNan L and Comin-Anduix, Begonya and Guemes, Miriam and Galic, Zoran and Phyu, Su and Okada, Hideho and Grausam, Katie B and Breunig, Joshua J and Brown, Christine E and Nathanson, David A and Prins, Robert M and Chen, Yvonne Y},
  title = {IL-13Rα2/TGF- β bispecific CAR-T cells counter TGF- β -mediated immune suppression and potentiate anti-tumor responses in glioblastoma},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {10},
  pages = {1850--1866},
  doi = {10.1093/neuonc/noae126}
}
Kostenlos starten →